{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:14:31Z","timestamp":1788491671248,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"10546","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/s0140-6736(26)00967-0","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:19:43Z","timestamp":1780773583000},"page":"2402-2413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial"],"prefix":"10.1016","volume":"407","author":[{"given":"Harpreet S","family":"Bajaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima-Zahra","family":"Jaouimaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiren","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bartee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(26)00967-0_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(26)00967-0_bib2","first-page":"S132","article-title":"6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes\u20142026","volume":"49","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(26)00967-0_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes?","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/S0140-6736(26)00967-0_bib4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","article-title":"The many faces of diabetes: a disease with increasing heterogeneity","volume":"383","author":"Tuomi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)00967-0_bib5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMra1011035","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shulman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)00967-0_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(26)00967-0_bib7","first-page":"S166","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes\u20142026","volume":"49","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(26)00967-0_bib8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)00967-0_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/S0140-6736(26)00967-0_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(26)00967-0_bib11","first-page":"S183","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142026","volume":"49","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(26)00967-0_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(26)00967-0_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)00967-0_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)00967-0_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)00967-0_bib16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2213-8587(25)00225-6","article-title":"Once-weekly semaglutide 7\u00b72 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial","volume":"13","author":"Lingvay","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(26)00967-0_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(26)00967-0_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/S0140-6736(26)00967-0_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.868037","article-title":"Is glucagon receptor activation the thermogenic solution for treating obesity?","volume":"13","author":"Concei\u00e7\u00e3o-Furber","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/S0140-6736(26)00967-0_bib20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/S0140-6736(26)00967-0_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)00967-0_bib22","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1080\/01621459.2022.2049278","article-title":"Toward better practice of covariate adjustment in analyzing randomized clinical trials","volume":"118","author":"Ye","year":"2022","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/S0140-6736(26)00967-0_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/19466315.2022.2025893","article-title":"Efficient estimation of the efficacy and safety endpoints for clinical trials with preplanned dose titrations","volume":"15","author":"Qu","year":"2022","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/S0140-6736(26)00967-0_bib25","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/clinem\/dgae038","article-title":"Tirzepatide improved markers of islet cell function and insulin sensitivity in people with T2D (SURPASS-2)","volume":"109","author":"Frias","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S0140-6736(26)00967-0_bib26","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1210\/clinem\/dgae319","article-title":"Effects of tirzepatide vs semaglutide on \u03b2-cell function, insulin sensitivity, and glucose control during a meal test","volume":"109","author":"Mather","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S0140-6736(26)00967-0_bib27","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00125-008-1116-7","article-title":"Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause","volume":"51","author":"Taylor","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/S0140-6736(26)00967-0_bib28","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)00967-0_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)00967-0_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-023-00817-4","article-title":"Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases","volume":"19","author":"H\u00e6dersdal","year":"2023","journal-title":"Nat Rev Endocrinol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673626009670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673626009670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:10:01Z","timestamp":1787832601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673626009670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"10546","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0140673626009670"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(26)00967-0","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(26)00967-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(26)01136-0","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}